Global MarketsNovember 9 at 09:46 AM

Zealand Pharma (ZEAL DC) announced that Boehringer Ingelheim has reported positive results from the Phase 3 SYNCHRONIZE-CVOT trial, the first global cardiovascular safety trial of a glucagon/GLP-1 dual agonist to date.

ORIGINAL · NewsquawkZealand Pharma (ZEAL DC) announced that Boehringer Ingelheim has reported positive results from the Phase 3 SYNCHRONIZE-CVOT trial, the first global cardiovascular safety trial of a glucagon/GLP-1 dual agonist to date.

StockNow breaking-news AI analysis

A 2026-11-09 report said Boehringer Ingelheim reported positive Phase 3 SYNCHRONIZE-CVOT results, but supplied no endpoints, numerical findings, or drug name.

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Zealand Pharma (ZEAL DC) announced that Boehringer Ingelheim has reported positive results from the Phase 3 SYNCHRONIZE-CVOT trial, the first global cardiovascular safety trial of a glucagon/GLP-1 dual agonist to date.

What do investors think?

Today's market highlights

Iran has reportedly dropped a demand to control the Strait of Hormuz and collect transit fees, Hayom reports citing officials; however, they are unwilling to discuss "or even signal a willingness to enter negotiations" on nuclear issues

[MARKET UPDATE]: Oil prices see further pressure on reports Iraq presented proposals to end Iran war to US President Trump, who expressed his approval; knee jerk move higher in equities and T-notes see modest gains

US Envoy Kushner says US President Trump is determined to bring an end to this horrible war, in relation to the Ukraine-Russia war